Phase IIa, 2:2:1 randomised, double-blind, placebo-controlled, parallel group, multi-centre clinical trial to investigate the safety, efficacy and pharmacokinetics of recombinant human soluble Fc-gamma receptor IIb (SM101) for intravenous application in the treatment of systemic lupus erythematosus (SLE) patients with or without a history of lupus nephritis.

Trial Profile

Phase IIa, 2:2:1 randomised, double-blind, placebo-controlled, parallel group, multi-centre clinical trial to investigate the safety, efficacy and pharmacokinetics of recombinant human soluble Fc-gamma receptor IIb (SM101) for intravenous application in the treatment of systemic lupus erythematosus (SLE) patients with or without a history of lupus nephritis.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2015

At a glance

  • Drugs SM 101 (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions
  • Acronyms SMILE
  • Sponsors SuppreMol
  • Most Recent Events

    • 04 Mar 2015 According to a Baxter International and SuppreMol GmbH media release, results were presented at the American College of Rheumatology, 2014 annual meeting.
    • 04 Mar 2015 Results published in a Baxter International and SuppreMol GmbH media release.
    • 21 May 2013 Proceeds from series D financing will be used to further advanced this study, according to a SuppreMol media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top